PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
about
Current management and perspectives for HCV recurrence after liver transplantationAntiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantationManagement of hepatitis c genotype 4 in the liver transplant settingInterferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug ResistanceManagement of Hepatitis C Post-liver Transplantation: a Comprehensive ReviewHepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and ManagementSurgical approach for hepatitis C virus-related hepatocellular carcinomaΜanagement of patients with hepatitis B and C before and after liver and kidney transplantationHepatitis C: New challenges in liver transplantationChallenges of recurrent hepatitis C in the liver transplant patientHuman monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzeesUtility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.Recurrent hepatitis C after liver transplantNatural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis.Future treatment of patients with HCV cirrhosis.Management of recurrent hepatitis C virus after liver transplantation.Griffithsin has antiviral activity against hepatitis C virusA human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjectsResponse-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver TransplantationOutcomes for patients with HCV after liver transplantation in Korea: a multicenter studyLiving-donor liver transplantation and hepatitis CHuman monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.New perspectives for preventing hepatitis C virus liver graft infection.Hepatitis C virus treatment pre- and post-liver transplantation.Telaprevir/boceprevir era: from bench to bed and back.Hepatitis B and C in liver transplantation: new strategies to combat the enemies.Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.Hepatitis C recurrence: the Achilles heel of liver transplantation.Management of HCV transplant patients with triple therapy.Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.Management of post transplant hepatitis C in the direct antiviral agents era.Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.Management of Post-Liver Transplant Recurrence of Hepatitis C.Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
P2860
Q22299427-8AA8FDC5-542A-4C9C-9FD6-94F25CF7FD32Q24202008-0B013112-1435-4BA4-8288-3B8727AE912AQ26749326-A331ED9A-90CD-469A-9490-7060C2057BB7Q26781331-2B4AFD07-F6F4-4520-98A0-606FBD5D881DQ26781741-6AA1ABD8-8189-4B4B-AFF0-DF187AE78AD5Q26781984-345D4487-3FE9-4E03-9E2D-3CBFA9F3709EQ26824046-DB5EDF2B-68A1-44C0-B9BB-BCC852E5A62AQ26864647-CAA45205-F354-4900-8559-9D12DBF62A75Q26999368-9C878AF3-0864-4CF8-BAD3-FCC94DBAE7F4Q27011871-52CF21DF-599C-42F4-96D3-F1DC02D109F4Q28483065-4DB86F72-F2D7-417B-9978-6C30DFB6AB97Q33423299-02241D99-3CE9-40FC-8052-FF0088755953Q34067825-BB829554-8EDC-47FB-9C54-391641978F5BQ34093754-DA67876D-2549-45B9-B24C-2550E0F34ADBQ34119509-7834CF00-3411-4DB2-AB0C-24EAF77596D7Q34243993-02E72250-8354-4E0B-B272-B50ED8CD3B11Q34589655-AC1F8EA0-9E9E-44B2-8038-A9B92AEEE291Q35363633-52D827DE-3B50-4890-A396-E8A8DF6C7664Q35685409-95DB070F-FF08-43EC-8FBF-527DBA25B326Q35790393-2D4E4560-5F51-41E0-B238-A3928F857BB4Q35980958-1A63C8F2-9D5C-4637-BA24-424DB1EE7863Q36241697-607DCFC0-7379-490F-836F-8CAC41BCCF95Q36476188-1F4A120A-9AE7-4661-8ED6-C13B6B80888DQ36587253-B87CBB83-162B-4F92-B0C1-43B8386B795EQ36745425-A187B468-C2D1-428D-AB6E-35A83CD36880Q37015805-75D3A92C-81C1-4ACE-B344-03F4A0DFF0C0Q37972771-B621087F-DE88-4D41-89C8-09EA96B1CB93Q38062524-147B85FB-F84F-4E30-A78D-ED57C2D03B72Q38067343-ABD8BEDD-85AA-49A3-82D7-485E596E0BD6Q38083754-B2DE8B65-9617-4535-A9F7-54FE5F077368Q38174194-E001B3A7-5C9D-4D2A-B44B-519EF5B12FEAQ38174249-291613F4-8C12-461A-89B9-79C6F4280A0AQ38204468-61C3729B-C934-4610-8E57-61E5D58F6AF4Q38265900-BCEF61F9-5E98-446A-AC07-9E96C357F854Q38395275-95F74795-3C45-4B09-9912-E8062BF0C55FQ38584289-B2695726-0BB6-447E-A7D0-076909E3A6FDQ39017681-C6FF9B83-E69F-49A7-8326-867ABD274B76Q39885523-DC8CA680-2278-4989-A58B-E6799F06D975Q40271866-BEC8137A-3C3E-4B8C-8593-D2BF51E04740Q41006072-7D76F66F-3D19-49A3-9811-8430D962BDCC
P2860
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PHOENIX: A randomized controll ...... ntation for hepatitis C virus.
@en
PHOENIX: A randomized controll ...... ntation for hepatitis C virus.
@nl
type
label
PHOENIX: A randomized controll ...... ntation for hepatitis C virus.
@en
PHOENIX: A randomized controll ...... ntation for hepatitis C virus.
@nl
prefLabel
PHOENIX: A randomized controll ...... ntation for hepatitis C virus.
@en
PHOENIX: A randomized controll ...... ntation for hepatitis C virus.
@nl
P2093
P2860
P356
P1476
PHOENIX: A randomized controll ...... ntation for hepatitis C virus.
@en
P2093
Avinash Prabhakar
David R Nelson
Gregory T Everson
Lichen L Teng
Michael R Charlton
Natalie Bzowej
Norah A Terrault
PHOENIX Study Group
P2860
P304
P356
10.1002/LT.22271
P577
2011-05-01T00:00:00Z